Related Experiment Video
Updated: Jun 20, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
[How to improve response to cardiac resynchronization therapy?]
1I. interní klinika Lékarské fakulty UP a FN Olomouc. Jan.Lukl@fnol.cz
Vnitrni Lekarstvi
|September 30, 2009
Summary
Cardiac resynchronization therapy improves heart failure outcomes, but 30% of patients show no response. This study identifies key factors influencing therapy success, including lead placement and scar tissue, to optimize patient selection and outcomes.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Context:
- Cardiac resynchronization therapy (CRT) is a standard treatment for heart failure, aiming to improve cardiac function and reduce mortality.
- A significant proportion of patients (approximately 30%) do not achieve optimal benefit from CRT, necessitating investigation into non-response factors.
- Understanding these factors is crucial for refining patient selection and improving CRT efficacy.
Purpose:
- To identify and analyze factors influencing patient response to cardiac resynchronization therapy.
- To explore methods for optimizing these identified factors to enhance CRT effectiveness.
- To determine criteria for considering alternative interventions, such as cardiosurgical lead implantation, or withholding CRT.
Summary:
- This study investigates predictors of non-response to cardiac resynchronization therapy (CRT) in heart failure patients.
- Key factors analyzed include left ventricular lead proximity to the latest activated segment, presence and size of post-infarction scar, and percentage of fully captured paced beats.
- Optimization strategies and criteria for alternative treatments or omitting CRT are discussed.
Impact:
- Improved patient selection for CRT, potentially increasing response rates and reducing unnecessary procedures.
- Enhanced understanding of the mechanisms underlying CRT non-response, guiding future research and device development.
- Personalized treatment approaches for heart failure patients, optimizing outcomes and resource utilization.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...